The regulatory mechanism that BCL6 could be transactivated by STAT1 was also observed in imatinib-treated chronic myeloid leukemia cells (Madapura et al., 2017) and contributed to CD4+ T follicular helper cell TFH differentiation and autoimmunity (Nakayamada et al., 2014). The gene discussed is BCL6; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.